OmicsVeu Launches An Extensive Line Of Spatial Biology Products For Multiplex Multi-omics
Fremont, Dec. 13, 2022 (GLOBE NEWSWIRE) — OmicsVeu, a wholly owned subsidiary of BioGenex, is pleased…
ISP
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company…
Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022
MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. today announced its NeXT Personal® cancer assay earned the top…
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent…
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts UTRECHT,…
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American…
Wilson & Company Names Ryan Branfort as Chief Information Officer
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Wilson & Company, Inc., Engineers & Architects is pleased to announce that…
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
Trem-cel (formerly VOR33) successfully manufactured and engrafted normally Blood counts successfully maintained following post-transplant treatment…
ONK Therapeutics Boosts Drug Development Experience and Expands US Presence with the Appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer
Bruce McCreedy Ph.D. joins the Executive Leadership Team as Chief Scientific Officer, as the company…
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis…
Web3 Working Group launches with $2M to drive adoption of Web3 infrastructure
Backed by Arweave,The Graph, Livepeer, and Akash, nonprofit aims to educate and drive adoption of…
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
IMUNON Announces Strategic Investment in Transomic Technologies
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE…
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent…
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested…
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited (ASX:IMU),…